GKOS - Moderna headlines weekly healthcare gainers; FibroGen and Biogen trail

Artystarty/iStock via Getty Images Thanks to the prospects of earning a spot in the S&P 500 Index, Moderna (MRNA) jumped ~23.0% this week to breeze past $100B market capitalization. The frontrunner in COVID-19 vaccine development has taken less than three years from its record-setting IPO in 2018 to trade neck and neck among some of the largest companies listed in the U.S next week. While Moderna led the biggest gainers among large-cap stocks, the nano-cap health tech firm SCWorx (WORX), with a ~59.9% rise, recorded the best weekly performance. Meanwhile, FibroGen (FGEN) trailed the sector with a ~45.8% loss on its failure to win the endorsement for a kidney disease therapy from an FDA-appointed expert panel. The micro-cap companies were dominated by Ayala Pharma (AYLA) which climbed ~45.4%, while IMV (IMV) lagged with a ~36.1% loss driven by $25M of capital raise announced over the week. Adagene (ADAG), a recent component of FTSE Russell Indexes, rose ~31.3% to lead small-cap healthcare stocks this week. The clinical-stage biotech company that went public

For further details see:

Moderna headlines weekly healthcare gainers; FibroGen and Biogen trail